Sun Life Exec Urged Strategic GLP-1 Coverage
The company identified rising GLP-1 claim volumes as a key factor in managing long-term cardiometabolic health risks.
Updated on Sept. 30, 2026 in Diabetes
Live Poll
Should employers prioritize long-term preventative health over reducing immediate pharmacy costs in their benefit plans?
Sun Life executive Jennifer Collier has advised employers to restructure their health plans to prioritize cardiometabolic risk strategies as GLP-1 claim volumes surged by 24 percent over the past year. The guidance emphasizes the need for evidence-based eligibility criteria and structured support to manage rising costs and medication adherence.
Why it matters
High out-of-pocket expenses are driving non-adherence among workers, while common comorbidities like cardiovascular disease and cancer continue to amplify the volume and total cost of medical claims for employers. Properly managing these risk factors is essential to stabilizing insurance spend.
Sun Life reported a 24 percent annual increase in GLP-1 claims and a 43 percent rise in spend for hepatic liver disease. The total annual spend for hepatic liver conditions reached $63.9 million, with the average claimant cost hitting $230,000.
The players
Jennifer Collier
She serves as a senior executive at Sun Life and is a lead advocate for evolving employer-sponsored health plan designs.
Sun Life
This international financial services organization provides insurance and benefits solutions to employers across the United States.
The details
Complex claims often feature multiple conditions, with 22 percent of high-cost claims combining cancer and cardiovascular issues, 11 percent pairing cancer and kidney disease, and 23 percent linking cancer with orthopedic conditions. Data also shows that 50 percent of patients using expert second opinions receive adjustments to their diagnosis or treatment plans.
Timeline
September 30, 2026: Sun Life released the report detailing GLP-1 coverage strategies.
Health Landscape
This strategy follows the standards for benefit design established by the Patient Protection and Affordable Care Act. It represents a significant shift in how insurers manage complex chronic condition coverage versus traditional legacy models.
Employees may face stricter evidence-based eligibility requirements when seeking coverage for GLP-1 medications under updated employer plans. Conversely, those pursuing expert second opinions may find more frequent changes to their treatment paths, which could improve diagnostic accuracy.
The takeaway
Employers are increasingly using structured support programs to mitigate the financial burden of complex comorbidities. Patients should verify their specific plan requirements to understand how new eligibility standards might affect their access to ongoing medication.
Further reading
For more information on the evolving landscape of chronic disease management, visit Diabetes.
Source note: This article includes information reported by Insurance Business.
Live Poll
Should employers prioritize long-term preventative health over reducing immediate pharmacy costs in their benefit plans?
